Aridis Pharmaceuticals Inc. (ARDS): Price and Financial Metrics

Aridis Pharmaceuticals Inc. (ARDS)

Today's Latest Price: $6.25 USD

0.27 (-4.14%)

Updated Dec 2 8:02pm

Add ARDS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ARDS Stock Summary

  • ARDS's price/sales ratio is 65.63; that's higher than the P/S ratio of 96.04% of US stocks.
  • ARDS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 3.15% of US stocks.
  • Revenue growth over the past 12 months for Aridis Pharmaceuticals Inc comes in at -58.54%, a number that bests just 3.69% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Aridis Pharmaceuticals Inc are IMGN, BLCM, CRIS, FULC, and KALV.
  • Visit ARDS's SEC page to see the company's official filings. To visit the company's web site, go to

ARDS Stock Price Chart Interactive Chart >

Price chart for ARDS

ARDS Price/Volume Stats

Current price $6.25 52-week high $10.18
Prev. close $6.52 52-week low $3.80
Day low $6.25 Volume 11,900
Day high $6.43 Avg. volume 10,822
50-day MA $7.09 Dividend yield N/A
200-day MA $6.85 Market Cap 62.91M

Aridis Pharmaceuticals Inc. (ARDS) Company Bio

Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. The company was founded in 2003 and is based in San Jose, California.

ARDS Latest News Stream

Event/Time News Detail
Loading, please wait...

ARDS Latest Social Stream

Loading social stream, please wait...

View Full ARDS Social Stream

Latest ARDS News From Around the Web

Below are the latest news stories about Aridis Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARDS as an investment opportunity.

Albireo's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

Albireo reports positive data from Phase 3 trial Albireo Pharma, Inc. (ALBO) reported positive top-line data from PEDFIC 1 trial for odevixibat. The study met both its primary endpoints. The drug candidate is a highly potent, non-systemic ileal bile acid transport inhibitor. It is being developed for treating progressive familial...

Avisol Capital Partners on Seeking Alpha | September 11, 2020

Aridis Pharma on go with mid-stage study of AR-501 in cystic fibrosis

Aridis Pharmaceuticals (ARDS) has reached an agreement with the FDA to simplify its AR-501 Phase 2 trial design for the treatment of chronic lung infections associated with cystic fibrosis ((CF)). After reporting (June 2020) positive Phase 1 safety data, Aridis proposed, and the FDA has now agreed, to streamline AR-501's...

Seeking Alpha | September 8, 2020

Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501

SAN JOSE, Calif., Sept. 8, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced it has reached an agreement with the US…

PR Newswire | September 8, 2020

Aridis Pharmaceuticals Announces Second Quarter 2020 Results

SAN JOSE, Calif., Aug. 11, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the…

PR Newswire | August 11, 2020

We Think Aridis Pharmaceuticals (NASDAQ:ARDS) Can Easily Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | July 15, 2020

Read More 'ARDS' Stories Here

ARDS Price Returns

1-mo -1.73%
3-mo -13.79%
6-mo -7.41%
1-year 31.58%
3-year N/A
5-year N/A
YTD 40.45%
2019 -59.87%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching ARDS

Want to see what other sources are saying about Aridis Pharmaceuticals Inc's financials and stock price? Try the links below:

Aridis Pharmaceuticals Inc (ARDS) Stock Price | Nasdaq
Aridis Pharmaceuticals Inc (ARDS) Stock Quote, History and News - Yahoo Finance
Aridis Pharmaceuticals Inc (ARDS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.9523 seconds.